The potential to target CCL5/CCR5 in breast cancer
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Chemokines play a crucial role in breast cancer tumorigenesis and progression. Recently, the chemokine (C-C motif) ligand 5 (CCL5), which can be secreted either by tumor cells or by mesenchymal stromal cells recruited to the tumor, has been identified as a key node in the bidirectional communication between breast cancer and normal cells. AREAS COVERED: In this review, the authors discuss the role of CCL5/chemokine receptor 5 (CCR5) axis in promoting breast cancer onset and progression. Interrogation of large clinical databases has demonstrated increased expression of the CCL5/CCR5 axis in specific subtypes of breast cancer. The activation of the receptor CCR5 in breast cancer cells controls their invasiveness serving as a driver for metastasis. Furthermore, the CCL5/CCR5 axis participates in the recruitment of specific immune cells into tumors, inducing local immunosuppression and favoring tumor progression. EXPERT OPINION: The role of CCR5 in HIV infection led to the development of specific and potent CCR5 antagonists. The data reviewed here includes basic and translational studies that support the use of such CCR5 antagonists in breast cancer patients as adjuvant therapy to block the metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 4×
“Accordingly, the authors suggest that after recruitment of MSCs populations into primary tumors, consequent interactions between the MSCs and breast cancer cells endow the latter with metastatic properties [39].”
BackgroundInfluentialGobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450 · cited 1×
“Disruption of CCL5 production by genetic knock-down in tumor cells decreases the recruitment of Tregs to the tumor microenvironment thereby reducing tumor growth [45].”
BackgroundFujimoto, H., Sangai, T., Ishii, G., Ikehara, A., Nagashima, T., Miyazaki, M., & Ochiai, A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24378 · Cited by 263 · cited 1×
“showed that there was significant positive correlation between stromal CCL2 (monocyte chemotactic protein 1) expression and macrophage infiltration but negative correlation between CCL5 expression and macrophage recruitment in breast cancer [55].”
BackgroundChaturvedi, P., Gilkes, D. M., Wong, C. C. L., Kshitiz, K., Luo, W., Zhang, H., Wei, H., Takano, N., Schito, L., Levchenko, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69244 · Cited by 181
Sun (2009) · Oncology Reports · doi:10.3892/or_00000331 · Cited by 84 · cited 1×
“CCL5 can be expressed and secreted by breast cancer cells [22-25].”
Background
Cited by
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
“Finally, it is possible that pleiotropic chemokines such as CCL5 can contribute to tumor progression by recruiting regulatory T cells (Velasco-Velázquez et al., 2014), obscuring the prognostic value of the three chemokine signature (data not shown).”
BackgroundDangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
“However, unlike in other tumor types (Halama et al., 2016; Velasco-Velazquez et al., 2014), we could not demonstrate coexpression of CCL5 and any of its receptors (CCR1, CCR3, or CCR5) on ovarian tumors cell lines (Figure S3A).”
BackgroundChemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 583
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
Metadata
- Authors
- Velasco-Velázquez, M., Xolalpa, W., & Pestell, R. G.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2014-09-26
- Volume
- 18
- Issue
- 11
- Pages
- 1265-1275
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2024411037
- Cited by
- 107
- References
- 6
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential to target CCL5/CCR5 in breast cancer. https://app.cochat.ai/papers/10.1517/14728222.2014.949238
- The paper
- Velasco-Velázquez, M., Xolalpa, W., & Pestell, R. G. (2014). The potential to target CCL5/CCR5 in breast cancer. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2014.949238
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.